ZRSR2 and cancer: Specifically, we uncover cancer vulnerabilities amongst synthetic lethal hits with EXO1 loss, including deficiencies in BRCA1-A complex factors, FA pathway genes and the splicing factor and tumour suppressor ZRSR2.